Ultimovacs - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

SenSen Networks

MCap

AUD24m

Last close

AUD0.03

▲ 0.01 (36.36%)

Lepidico

MCap

AUD39m

Last close

AUD0.00

▲ 0.00 (33.33%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Price performance
Financials
Research
Thematics

Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

View More

Healthcare |
Flash note

18.04.24

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare |
Flash note

07.03.24

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare |
Flash note

04.03.24

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare |
edison tv

27.02.24

Ultimovacs – executive interview

Ultimovacs_resized

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Jyoti Prakash

Analyst, Healthcare

Associate analyst

Key Management

Carlos de Sousa

CEO
Gustav Gaudernack

CSO
Hans Vassgård Eid

CFO
Jens Bjørheim

CMO
Ton Berkien

CBO

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(12.4)	(95.0)	(94.5)
Relative	(14.9)	(95.4)	(95.0)
52 week high/low	NOK160.4/NOK6.3

Financials

Ultimovacs is focused on developing a cancer vaccine with universal potential. Lead asset UV1 activates the immune system to recognise cancer cells that express hTERT, which is present in c 85–90% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total, with readouts across 2023–25. While UV1 has demonstrated efficacy in mesothelioma (NIPU), recent results in melanoma (INITIUM) did not show the expected added benefit with UV1. The next readouts in head and neck cancer (FOCUS) are expected in Q324.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2022A	0.0	(181.0)	(167.8)	(489.9)	N/A	N/A
2023A	0.0	(213.0)	(189.2)	(550.1)	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A
2025E	N/A	N/A	N/A	N/A	N/A	N/A

Ultimovacs_resized

Flash note

Healthcare

02.11.23

Ultimovacs — Line of sight on INITIUM top-line readout

research

Healthcare

18.10.23

Ultimovacs — Overall survival is the name of the NIPU PII game

Ultimovacs_resized

Flash note

Healthcare

12.10.23

Ultimovacs — Two for two in melanoma Phase I trial

Ultimovacs_resized

Flash note

Healthcare

10.10.23

Ultimovacs — UV1 ODD a sign of positive things to come

Update

Healthcare

24.08.23

Ultimovacs — Gearing up for UV1 Phase II trial readouts

Flash note

Healthcare

04.08.23

Ultimovacs — FOCUS – first in series of upcoming catalysts

Ultimovacs_resized

Flash note

Healthcare

20.06.23

Ultimovacs — Positive Phase I update in malignant melanoma

Update

Healthcare

12.06.23

Ultimovacs — UV1 by no means out after NIPU readout

Update

Healthcare

15.05.23

Ultimovacs — All steady as Phase II trial readouts approach

Update

Healthcare

26.04.23

Ultimovacs — NIPU and INITIUM readouts incoming for UV1

Ultimovacs_resized

Update

Healthcare

21.02.23

Ultimovacs — Gathering steam with multiple inflections in FY23

Flash note

Healthcare

23.01.23

Ultimovacs — Phase II milestone as licensing potential nears

Flash note

Healthcare

21.12.22

Ultimovacs — Slight adjustment but trial continues as planned

Flash note

Healthcare

15.12.22

Ultimovacs — Prostate cancer trial patient enrolment complete

Update

Healthcare

11.11.22

Ultimovacs — On track for upcoming UV1 catalysts

Flash note

25.10.22

Ultimovacs — First patient in Phase II LUNGVAC study

edison tv

Healthcare

21.10.22

Ultimovacs – executive interview

Flash note

18.10.22

Ultimovacs — Biomarker insight into UV1 combination

edison tv

Healthcare

17.10.22

Ultimovacs – executive interview

Flash note

06.10.22

Ultimovacs — UV1 encouraging three-year survival data

Flash note

Healthcare

13.09.22

Ultimovacs — Further positivity for UV1

Update

Healthcare

19.08.22

Ultimovacs — UV1 development funded past key readouts

Flash note

Healthcare

19.08.22

Ultimovacs — Patient expansion in Phase I TENDU

Flash note

Healthcare

21.06.22

Ultimovacs — Positive Phase I survival data in melanoma

Update

Healthcare

15.06.22

Ultimovacs — Patient enrolment continues; catalysts approach

Flash note

Healthcare

13.05.22

Ultimovacs — UV1 Phase II data flow creeps closer

edison tv

Healthcare

07.03.22

Ultimovacs – executive interview

edison tv

Healthcare

16.01.22

Ultimovacs – executive interview Test

Update

Healthcare

13.12.21

Ultimovacs — New large indication for UV1

Update

Healthcare

03.09.21

Ultimovacs — Data continue to impress in Phase I UV1 study

Update

Healthcare

21.05.21

Ultimovacs — ORR impressive in Phase I UV1 plus Keytruda

Initiation

Healthcare

17.03.21

Ultimovacs — Cancer vaccine with virtually universal potential

edison tv

Healthcare

03.02.21

Ultimovacs – Edison Open House interview

QuickView

Healthcare

20.01.21

Ultimovacs — Phase II data from 500+ patients over 2022/23

QuickView

Healthcare

20.11.20

Ultimovacs — Cancer vaccine with near-universal potential